Del-zota (delpacibart zotadirsen) produced statistically significant increases in exon skipping and dystrophin levels in EXPLORE44®, a Phase 1/2 study in individuals with DMD44

Phase 3, Randomized, Global Study Assessing Efficacy and Safety of Del-desiran™ for the Treatment of Myotonic Dystrophy Type 1: HARBOR™ Trial Design

Novel Precision Cardiology Treatment for PRKAG2 Cardiomyopathy, a Subset of Patients with Wolff-Parkinson-White Syndrome

Phase 3, Randomized, Global Study Assessing Efficacy and Safety of Del-desiran™ for the Treatment of Myotonic Dystrophy Type 1: HARBOR™ Trial Design

Interim Results from FORTITUDE™, a Randomized Phase 1/2 Trial Evaluating AOC 1020 in Adults with FSHD

Interim results from FORTITUDE™, a randomized Phase 1/2 trial evaluating AOC 1020 in adults with FSHD

Increasing Diversity in Clinical Trial Participation: An Exploration of Clinical Trial Site Engagement

Effect of Long-Term Treatment of AOC 1001 in Adults with Myotonic Dystrophy Type 1: from MARINA® to MARINA-OLE™

AOC 1001-Mediated Reduction of DMPK Leads to Increase in Functional MBNL Levels, Improving Muscle Function in Patients with DM1

Initial results of the Phase 2 Open-Label Extension Study of AOC 1001 in Adults with Myotonic Dystrophy Type 1: MARINA-OLE™

AOC 1001-mediated Reduction of DMPK Leads to Increase in Functional MBNL Levels, Improving Muscle Function in Patients with DM1

AOC 1044 as a Novel Therapeutic Approach for DMD Patients Amenable to Exon 44 Skipping: EXPLORE44 Phase 1/2 Healthy Volunteer Data

Targeting DUX4 for Silencing with AOC for the Treatment of FSHD

Increasing Diversity in Clinical Trial Participation: An Exploration of Clinical Trial Site Engagement

Topline Safety and Efficacy Data Analysis of Phase 1/2 Clinical Trial Evaluating AOC 1001 in Adults with Myotonic Dystrophy Type 1: MARINA™

AOC 1001 Demonstrates DMPK Reduction and Spliceopathy Improvement in a Phase 1/2 study in Myotonic Dystrophy Type 1 (DM1) (MARINA™️️️)

Topline Data Analysis of the Phase 1/2 Clinical Trial Evaluating AOC 1001 in Adult Patients with Myotonic Dystrophy Type 1: MARINA™️️️

Phase 1/2 Trial Evaluating AOC 1044 in Healthy Volunteers and Participants with DMD Mutations Amenable to Exon 44 Skipping: EXPLORE44™️️️ Trial Design

Phase 1/2 Study to Evaluate AOC 1020 for Adult Patients with Facioscapulohumeral Muscular Dystrophy: FORTITUDE™️️️ Trial Design

Sex-related Utilization Differences in the 12-months After a Diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD)

More Prevalent Comorbidities, Healthcare Costs, and Service Utilization in Male Myotonic Dystrophy (DM) Patients and Female Patients

Phase 1/2 Trial Evaluating AOC 1044 in Healthy Volunteers and Participants with DMD Mutations Amenable to Exon 44 Skipping (DMD44): EXPLORE44™️ Trial Design

Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of AOC 1020 Administered Intravenously to Adult Patients with Facioscapulohumeral Muscular Dystrophy (FORTITUDE™️) Trial Design

From Myotube to Patient: AOC 1001 Demonstrates DMPK Reduction and Spliceopathy Improvement in a Phase 1/2 Study in Myotonic Dystrophy Type 1 (DM1) (MARINA™️️️)

Topline Data Analysis of the Phase 1/2 Clinical Trial Evaluating AOC 1001 in Adult Patients with Myotonic Dystrophy Type 1: MARINA™️️️